

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 January 2005 (27.01.2005)

PCT

(10) International Publication Number
WO 2005/007241 A1

(51) International Patent Classification⁷: **A61P 33/14**,
A61K 31/609, 31/365

(21) International Application Number:
PCT/GB2004/003006

(22) International Filing Date: 12 July 2004 (12.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0316377.1 12 July 2003 (12.07.2003) GB

(71) Applicant (for all designated States except US): **NOR-
BROOK LABORATORIES LIMITED** [GB/GB]; Sta-
tion Works, Newry BT35 6JP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BLAKELY, William**
[GB/GB]; 79 Chapel Road, Killeavy, Newry, County Down
BT35 8JZ (GB). **CROMIE, Lillian** [GB/GB]; 65 Old War-
renpoint Road, Newry, County Down BT34 2PN (GB).

(74) Agent: **FITZPATRICKS**; 1 Blythwood Square, Glasgow
G2 4AD (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PARASITICIDAL COMPOSITION

(57) Abstract: An anti-parasiticide composition presented as a topical "pour-on" product for treating animals infected by parasites which are known to be susceptible to salicylanilides, especially closantel, alone or together with at least one other anti parasitic compound of the avermectin or milbemycin type and offers enhanced bioavailability of the salicylanilide by provision of a delivery system comprising at least 20%(v/v) of one or more alcohols, and optionally including a polymeric moiety selected from the group consisting of polyvinylpyrrolidone (PVP), polyoxypropylene/polyoxyethylene block copolymers (poloxamer), and polyethylene glycols (PEG), thereby improving the bioavailability of e.g. closantel (as assessed with respect to blood plasma levels of closantel).



WO 2005/007241 A1

Parasiticial Composition

Field of the Invention

This invention relates to parasiticial compositions, especially combination products for veterinary use, based on a salicylanilide optionally together with
5 another parasiticial agent, for example an avermectin or milbemycin, Such combination products exhibit efficacy across a broader spectrum of parasites than is observed with the use of a single parasiticial agent alone.

Background of the Invention

Warm-blooded animals are subject to attack by parasites, and man has
10 long sought to combat such parasites afflicting domestic companion animals, farmed livestock and exotic animals, to alleviate suffering and for commercial gain. The manner of attack by the parasites, and the identification of a sensitive stage in the life cycle of the parasite, may influence greatly the choice of combating agent. Thus percutaneous treatments using topically applied
15 preparations such as lotions, paints, creams, gels, dusting powders, "pour-ons" and dips are commonly suitable for ectoparasites, but combating endoparasites requires careful selection of the method of administration and the delivery system. Oral drenches, pastes, boluses, tablets, and granules for incorporating into feed mixes are known methods capable of being used by the animal
20 husbandrymen, but other methods which are intended to avoid use of the gastrointestinal route are typically administered by qualified practitioners. Such other methods include use of aerosols, and parenteral drug compositions which are selectively prepared as solution or suspension or micronised powder formulations intended for subcutaneous, intracutaneous, and intramuscular
25 injection according to the intended delivery regime. These last methods require special care in formulation to avoid irritation at the site of injection or possible adverse allergic or pyrogenic reactions.

Formulations are typically prepared using aqueous or non-aqueous ("solvent") vehicles. The latter class may comprise physiologically tolerable
30 alcohols, glycols, esters, a limited range of organic aromatic solvents, and vegetable oils and extracts or modified forms thereof. In selecting vehicles, the skilled worker has to consider a number of issues including, solubility of the

intended active ingredient(s), the affinity of the drug to certain vehicles, whether it will affect any essential auxiliaries, pH, stability over time, viscosity, and naturally the risk of any toxic effect upon the animal to be treated. In the case of a "pour-on" formulation, the ability to facilitate the transfer of the active ingredient or
5 ingredients through the skin and into the bloodstream to provide an efficacious dose is an essential feature of the composition. Therefore, formulation of a parasiticide is a complex task.

Traditional parasiticides include chemical agents such as the benzimidazoles, and carbamates, and plant extracts such as the pyrethroids,
10 which tend to be used to combat ectoparasites such as ticks and mites.

The salicylanilides, tend to be effective against fungal attack, but the chemically modified derivative closantel is an effective worming agent. Closantel is described in US 4 005 218 and in the literature, e.g. J.Guerrero *et al*,
J.Parasitol.**68**,616, (1983); H.Van den Bossche *et al*, Arch.Int.Physiol.Biochim,
15 **87**, 851(1979); H.J.Kane et al, Mol.Biochem.Parasitol.**1**, 347(1980).

Closantel is typically administered by the oral route e.g. as a bolus, or oral drench, or parenterally as an injection solution. WO 95/05812 suggests that an injectable anthelmintic composition containing abamectin and closantel can be produced with glycerol formal optionally using a glycol-based solvent such as
20 polyethylene glycol 400, or propylene glycol. However, because the topical route of administration is generally slower than any other routes (injection or oral route), absorption of closantel through the skin would be expected to be very slow, therefore closantel plasma levels would be expected to be lower than that obtained by delivery by any other route.

25 Closantel is also very hydrophobic and is very quickly and substantially bound to plasma proteins, this again would suggest to those skilled in the art that administration by topical means would reduce the achievable plasma concentration.

Therefore, currently there is no known commercial formulation adapted for
30 administration of closantel as a pour-on.

The avermectins are very potent antiparasitic agents which are useful against a broad spectrum of endoparasites and ectoparasites in mammals as well as having agricultural uses against various parasites found in and on crops and soil. The basic avermectin compounds are isolated from the fermentation
5 broth of the soil micro-organism *Streptomyces avermitilis* and these compounds are described in US patent US 4 310 519. Furthermore, derivatives of these basic avermectin compounds have been prepared by a variety of chemical means.

Some of the avermectin group of compounds contain a 22, 23-double
10 bond and others contain a disaccharide at the 13-position which consists of α -L-oleandrosyl- α -L-oleandrosyl group. One or both saccharide units can be removed forming a monosaccharide or an aglycone (where both saccharides are removed) as described in US patent US 4206205. The aglycone derivatives possess a hydroxy group at the 13 position which may be removed to form the
15 13-deoxy compound as described in the patents US 4 171 314 and US 4 173 571. Acylation of hydroxy groups on the avermectin compounds and derivatives can be carried out as described in US 4 201 861.

The milbemycin series of compounds, disclosed in US 3 950 360, are structurally similar to the avermectin family in that they contain the sixteen
20 membered macrocyclic ring. However, they do not contain the disaccharide subunit and there are differences in the substituent groups.

Ivermectin, disclosed in US 4 199 569, is prepared by the selective reduction of the 22, 23 double bond of the avermectin compounds. Ivermectin is a mixture of 22, 23-dihydro Avermectin B1a and B1b in a ratio of at least 80:20.

Ivermectin is an especially preferred active component in pesticidal
25 compositions, and there is extensive literature on its activity, demonstrating its efficacy against internal and external parasites, and its ability to interfere in the life cycle of certain parasites. The Merck Index (1996) cites several references including J.C.Chabala *et al*, J.Med.Chem.**23**, 1134 (1980); J.R.Egerton *et al*,
30 Brit.Vet.J.**136**, 88 (1980); W.C.Campbell *et al*, Science **221**, 823-828 (1983) to mention but a few.

Formulation of ivermectin for the purposes of delivery in a variety of presentations, e.g. as an oral drench, pour-on, parenteral formulations, granules for adding to feed, and syringeable pastes has proved highly challenging and numerous patents have been published on its use. Ivermectin exhibits a
5 lipophilic character but it can be solvated in aqueous systems, and various patents describe special solvent systems for use in its formulation. Thus reference may be made at least to EP 0 045 655, and EP 0 146 414 for example.

Although ivermectin is surprisingly effective, and has enjoyed a long period
10 of commercial success, there remains a keen interest in exploiting ivermectin against a wider range of parasites and in overcoming tolerance by some parasites which demands higher amounts of ivermectin to be delivered. Taking into account the fact that a significant volume of use of ivermectin is in protecting and treating animals intended for slaughter for human consumption, there are
15 constraints on the residual amount of active components such as ivermectin in the carcass of such an animal. Therefore, high loadings of ivermectin, even if technically feasible, in a delivery system are not necessarily the optimum solution.

Combination formulations are also desirable taking account of acquired
20 tolerance or resistance in pests to prolonged usage of other more traditional parasitocidal agents. This phenomenon is well documented, e.g. in relation to worming compositions. Synergistic effects or complementary effects of combined parasitocidal agents have been observed as a route to combating the aforesaid tolerance problem. Synergistic anthelmintic compositions are
25 discussed in WO 94/28887, which focuses on substituted mono- and bisphenols, salicylanilides, benzene sulphonamides, halogenated benzimidazoles, benzimidazoles, and benzimidazole carbamates.

The opportunity to combine the use of avermectins with other parasitocidal agents has been explored already. Thus one finds that skin-absorbable pour-on
30 formulations containing triclabendazole, optionally containing an avermectin, tetramisole or levamisole have been proposed in WO 0061068. An injectable formulation containing closantel together with an avermectin or milbemycin has

been proposed in WO 95/05812. Formulations of the pour-on and injectable type are suggested in WO 01/60380, which comprise use of a pyrrolidone solvent and a bridging solvent such as a xylene, optionally including a further solubility agent such as propylene glycol caprylic acids and esters or peanut oil. This special
5 solvent system is needed to address the difficulties of formulating differing parasiticidal agents such as closantel and ivermectin together. No disclosure of the efficacy of these formulations is made.

Other non-aqueous pour-on formulations are disclosed in WO97/13508, using a range of solvents, particularly polyalcohols, their ethers and mixtures
10 thereof, optionally in combination with various co-solvents. Whilst that reference does present results of trials of formulations disclosed therein they show limited success in achieving transfer of the active components into the bloodstream of the treated animal as discussed hereafter in the comparative Example.

Salicylanilide derivatives such as closantel provide useful control over a
15 range of parasites and are especially useful against liver fluke. The avermectin group of anti-parasitic compounds of which ivermectin is the best known example, provide complementary protection against many other parasites such as roundworms. Therefore, there are advantages to be gained if a combination of these drugs could be provided in a form that can be conveniently administered
20 to livestock and which will provide effective control of parasitic infection.

In particular the provision of an effective pour-on formulation containing closantel and ivermectin is therefore a highly desirable goal. The provision of a satisfactory formulation is problematical because the solubility regime for each drug is different. An alkaline system provides the optimum pH for closantel,
25 whereas ivermectin requires an acidic medium for satisfactory dissolution.

Objects of the Invention

It is an object of the present invention to provide improved veterinary pharmaceutical preparations. In particular it is an object of the invention to provide a composition having activity against a broad range of endo- and
30 ectoparasites including flukes. It is a further object of this invention to provide preparations that are suitable for topical administration, preferably presenting

closantel as a pour-on formulation. A still further object of the invention is to provide a veterinary pharmaceutical product combining closantel and ivermectin in an effective formulation enabling enhanced bioavailability of closantel in excess of those known in the prior art.

5

Summary of the Invention

Surprisingly it has been found that a salicylanilide, optionally with another anthelmintic, can be dissolved in one or more alcohols and that this formulation is useful as a "pour-on" formulation that provides efficacious levels of the salicylanilide, and the other anthelmintic, in the blood of an animal when it is
10 topically applied to the skin of the animal over a pre-determined period of time.

Accordingly, the invention enables the provision of effective pour-on parasitocidal compositions, especially combination products, containing closantel or the like salicylanilides, particularly binary formulations based on a salicylanilide together with another parasitocidal agent, for example of the avermectin or
15 milbemycin type, with effective bioavailability of the parasitocidal agents.

The inclusion of a polymeric moiety can enhance the efficacy of a pour-on parasitocidal composition of the present invention. One suitable polymeric moiety is polyethylene glycol (PEG) or a polyvinylpyrrolidone (PVP), but other polymeric moieties may be used, e.g. a polyoxypropylene/polyoxyethylene block copolymer
20 (poloxamer). Combinations of these polymeric moieties are also contemplated for the implementation of the invention described herein. The amounts thereof are variable, but from at least 0.1%(w/v) and up to 35%(w/v) or more of the polymeric moiety should be considered, with an amount of about 20%(w/v) being preferred.

25

It is considered that the presence of a polymeric moiety, like PEG, increases the level of closantel that can be dissolved in the pour-on formulation of the present invention.

30

According to a first aspect of the invention, a salicylanilide, especially closantel is presented in a pour-on formulation *characterised by* the presence of a delivery system comprising at least 20%v/v of one or more alcohols. The preferred alcohols are monohydric aliphatic or aromatic alcohols, more preferably

lower alkanols (C_1 - C_6). The most preferred delivery system comprises at least 20%v/v ethanol with isopropanol being additionally used to bring the formulation to 100% v/v for use.

Typically the delivery system of this particular invention further comprises
5 a polymeric moiety selected from polyethylene glycol (PEG), polyvinylpyrrolidone (PVP) and polyoxypropylene / polyoxyethylene block copolymers (poloxamers). When the delivery system comprises PEG, PVP, or a poloxamer, it is found that this provides pour-on formulations offering additional permeation of the active component(s) through the skin thus increasing the available amount of active
10 drug in the plasma of the treated subject.

The delivery system may be made up for use with typical formulation auxiliaries such as surfactants, embittering denaturants (anti-licking), preservatives, spreading aids penetration or occlusion enhancers, and anti-oxidants, e.g. butylated hydroxy toluene (BHT), butylated hydroxy anisole (BHA),
15 or sodium formaldehyde-sulphoxylate.

According to another aspect of the invention, a parasitocidal composition comprises a first parasitocidal agent selected from amongst the salicylanilides, together with another parasitocidal agent selected from the avermectins and the milbemycins, in a delivery system comprising at least 20%v/v of one or more
20 alcohols. The delivery system may include primary, secondary, tertiary and aromatic alcohols. The preferred alcohols are monohydric aliphatic or aromatic alcohols, more preferably lower alkanols (C_1 - C_6). The most preferred delivery system comprises at least 20%v/v ethanol with isopropanol being additionally used to bring the formulation to 100% v/v for use. Typically the solution of this
25 particular invention further comprises a polymeric moiety selected from polyethylene glycol (PEG), polyvinylpyrrolidone (PVP) and polyoxypropylene / polyoxyethylene block copolymers (poloxamers).

Thus use of an alcohol e.g. ethanol alone or in combination with isopropanol and/or a polymeric moiety such as PEG, PVP or a poloxamer is
30 found to be effective in the manufacture of a pour-on parasitocidal composition comprising closantel having long acting efficacy, such that the amount of polymeric moiety used enables the desired period of efficacy to be designed into

the formulation to provide a controllable period of effective treatment whilst still permitting slaughter for human consumption of the treated animal if required having regard to the legally prescribed withdrawal period. The polymeric moiety maintains the solubility of closantel in the delivery system, especially in the presence of water. Further, the use of a polymeric moiety such as PEG or PVP does not inhibit the bioavailability of an avermectin such as ivermectin present in a formulation according to the invention, showing that pour-on formulations, comprising a polymeric moiety e.g. PVP, poloxamer, PEG, or a combination thereof can be used for the effective delivery of active ingredients of a diverse nature and will therefore be likely to find wide utility in the field of animal health.

A suitable delivery system comprises a solvent and co-solvent(s) selected from the group consisting of aliphatic and aromatic alcohols, i.e. primary, secondary, tertiary and aromatic alcohols. The preferred alcohols are monohydric aliphatic or aromatic alcohols, more preferably lower alkanols (C₁-C₆). The most preferred delivery system comprises at least 20%v/v ethanol with isopropanol being additionally used to bring the formulation to 100% v/v for use. Preferably, one of said alcohols is ethanol present in an amount of at least 20% v/v and another alcohol is isopropanol which can be used to bring the solution up to 100%v/v for use.

Alternatively the delivery system comprises a lower aliphatic alcohol such as ethanol with a glycol solvent such as a PEG solvent, to which is added isopropanol to bring the solution to 100% (v/v) for use.

A range of PEG solvents according to molecular weight is commercially available, and any of those, or others that may yet be made available, may be chosen for convenience provided that the PEG is presented or rendered available as a liquid during formulation. Typically, PEG 200 to 6000 are readily to hand from commercial sources, and thus can be used for the purposes herein, but PEG 200 to PEG 600 are usefully employed in this invention. A preferred delivery system comprises the solvents PEG 200 with ethanol and isopropanol, together with a polymeric moiety (e.g. PVP) to enhance permeability.

A proportion of the PVP may be substituted by higher molecular weight polyethylene glycols, up to a molecular weight of 20000.

Thus according to the invention, it is now possible to obtain in a single pour-on formulation, a salicylanilide, preferably closantel, and an avermectin, preferably ivermectin, which is effective to deliver closantel when administered to an animal such that an effective plasma concentration of both closantel and ivermectin is readily achieved. Of course formulations containing just one of these active ingredients can be utilised if desired for clinical reasons.

The potential ranges of the preferred parasitocidal agents useful in such formulations are:

Closantel – from 1 to 30% w/v, preferably 1 to 15% w/v.;

Ivermectin - from 0.1 to 10% w/v, preferably 0.1 to 5 % w/v;

The quantity of polymeric moiety, especially PEG required to be effective depends on the desired salicylanilide activity of the mixture but preferably at least 3%(w/v) PEG, more preferably 20%(w/v) is used to permit the higher effective amounts of e.g. closantel desired to be achieved. The amount of polymeric material used is only limited by the amount of alcohol used in the delivery system, and thus could be up to 80%v/v.

Description of the drawing

The accompanying single figure drawing referred to hereinafter illustrates, by way of a graph, a comparison of pharmacokinetic profile of a formulation of the invention with a commercially available product.

Modes for Carrying Out the Invention

The invention will now be further described by way of illustrative example according to the best modes currently known.

Formulation Examples

In the preparation of a binary combination product for delivery in a pour-on presentation, the active components closantel and ivermectin were provided in amounts to deliver 10%(w/v) closantel and 0.5%(w/v) ivermectin. The delivery systems used included the solvents PEG 200, ethanol and isopropyl alcohol

which readily provided for effective solvation of the actives, together with a permeability enhancer, the compositions of several illustrative formulations are as follows:

Formulation 1

5	Ivermectin	0.25% w/v
	Closantel	5.0% w/v
	Ethanol	30% v/v
	Isopropyl Alcohol to	100% v/v

Formulation 2

10	Ivermectin	0.5%w/v
	Closantel (as Na salt)	10.0%w/v
	PVP	15.0%w/v
	Ethanol	20%v/v
	PEG 200	20%v/v
15	Isopropyl Alcohol	to 100%v/v

Formulation 3

	Ivermectin	0.5%w/v
	Closantel	10%w/v
	PVP	6%w/v
20	Crodamol CAP (emollient ester mix)	10%w/v
	Tributyl Citrate	0.3%w/v
	Polyethylene Glycol 200	20%v/v
	Ethanol	20%v/v
	Denatonium Benzoate	0.05%w/v
25	Isopropyl alcohol	q.s. to 100%

General Method of Formulation:

These formulations were made up following usual industry practice.

Administration Example

The formulations (1, 2 and 3) made as described above were presented
 30 for administration according to accepted industry procedures and the testing thereof is presented below.

The formulation containing closantel and ivermectin according to the above compositions (formulation 1, 2 and 3) were applied to cattle at an ivermectin-dose rate equivalent to 500 μ g/kg of bodyweight, and a closantel-dose rate of 10mg/kg of bodyweight.

- 5 The blood plasma results for closantel are shown in Tables 1, 4 and 5 and for ivermectin in Tables 2, 3 and 6.

Table 1

Plasma Levels of Closantel (μ g/ml) after Pour on Administration of Formulation 1 at a dose rate of 10 mg/kg bodyweight on one occasion

Hours	Closantel Mean	SEM
24	2.0	1.21
48	10.3	3.57
60	14.44	4.75
72	18.18	5.6
80	19.63	6.01
96	21.57	6.46
120	22.10	6.53
168	24.98	7.28
240	26.96	7.53

Table 2

Plasma levels of Ivermectin (ng/ml) in Cattle after pour-on administration of Formulation 1 at a dose rate of 500 μ g/kg bodyweight on 1 occasion

Hours	Ivermectin	
	Mean	SEM
24	4.95	1.14
48	14.53	3.49
60	16.60	5.44
72	19.11	6.23
80	19.94	6.19
96	19.73	6.41
120	18.27	5.61
168	16.18	5.03
240	10.55	3.23

5

Table 3

Plasma levels of Ivermectin (ng/ml) in Cattle after pour-on administration of Formulation 2 at a dose rate of 500 μ g/kg bodyweight on 1 occasion

	Hours	Mean	SEM
	24	19.19	14.91
10	48	19.45	12.56
	72	13.84	6.82
	96	11.98	5.32
	120	9.48	3.79
	144	7.77	3.28
15	168	6.38	2.47
	192	4.96	2.02
	216	3.97	1.31
	240	3.95	1.22
	264	3.22	1.07

Table 4
Plasma Levels of **Closantel** ($\mu\text{g/ml}$) after Pour on Administration of
Formulation 2 at a dose rate of 10 mg/kg bodyweight on one occasion

	Hours	Mean	SEM
5	24	5.45	1.65
	48	40.80	22.31
	72	48.60	25.01
	96	49.03	24.07
	120	49.27	22.88
10	144	47.07	23.36
	168	46.53	21.77
	192	51.47	27.06
	216	50.43	29.37
	240	50.17	26.79
15	264	25.85	11.06

Table 5
Plasma levels of **Closantel** ($\mu\text{g/ml}$) after Pour on Administration of
Formulation 3 at a dose rate of 10 mg/kg bodyweight on one occasion

Hours	Mean	SEM
24	36.2	12.2
48	42.8	23.4
54	43.8	23.6
72	52.2	29
78	55.6	30.2
96	47.2	24.6
120	45.4	22.6
192	39	20.2
240	34.6	10.4

TABLE 6
Plasma levels of Ivermectin (ng/ml) in Cattle after pour-on administration of
Formulation 3 at a dose rate of 500 μ g/kg bodyweight on 1 occasion

Hours	Mean	SEM
24	15.64	4.54
48	28.76	8.84
54	25.40	6.70
72	19.79	4.68
78	17.89	4.07
96	15.25	3.90
120	12.75	1.59
192	7.88	1.43
240	6.22	1.21

5

From Tables 2, 3 and 6 it can be seen that the plasma levels achieved for ivermectin are suitable for the treatment of cattle in that they achieve levels of ivermectin similar to those obtained using a commercially available (ivermectin only) product.

10 From Tables 1, 4 and 5 it is noted that the closantel levels achieved are those that are desired for a clinically effective product given that plasma concentration is crucial for the clinical flukicidal efficacy of the product. It is known that successful flukicidal activity is based upon the plasma concentration of the flukicide - as the plasma concentration increases the age of the fluke that
 15 can be exterminated decreases therefore increasing the possibility of a complete cure. With the closantel plasma concentrations demonstrated in Table 1, 4 and 5, it would be surmised that the formulation of the Norbrook invention would be effective against both adult and immature fluke.

20 The results obtained for closantel are also notably superior to those obtained in WO 97/13508 wherein a topical dose rate of 10 mg/kg closantel produced a maximum blood plasma level of only 8.37 μ g/ml (at 10 days). The

formulations of that application required a dose of 40 mg/kg in order to achieve a blood plasma level of 52.97 mg/kg. The results from that document for a 10 mg/kg dose are compared graphically with those of Table 2 in the Figure. It can be clearly seen that the formulation of the Norbrook invention provides for a

5 vastly superior pharmacokinetic profile in terms of maximum concentration and in duration of activity indicating that the Norbrook invention would provide for a product with superior clinical efficacy against flukes of all stages. In order to achieve such a profile the formulation of WO 97/13508 had to be administered at 40mg/kg - such a very high dose rate of closantel, in order to achieve desirable

10 plasma levels, poses a high risk of toxicity to the animal thus negating the pharmacokinetic profile. Therefore it can be seen that the compositions according to the present invention are surprisingly superior to the known art.

Industrial Applicability


In view of the aforesaid advantages and properties of the compositions

15 described herein, the invention will be usefully applied in the field of veterinary medicine in particular for combating endoparasites and ectoparasites typically afflicting livestock such as bovines, equines, ovines and caprines.

CLAIMS

1. An anti-parasitic pour-on composition characterised by the presence of a delivery system comprising at least 20% (v/v) of one or more alcohols, and
5 an effective amount of a salicylanilide anti-parasitic compound.
2. An antiparasitic composition according to claim 1, further comprising an effective amount of at least one other anti-parasitic compound.
3. A composition according to claim 1, wherein the salicylanilide is closantel or a pharmaceutically acceptable salt thereof.
- 10 4. A composition according to claim 2 or claim 3, wherein the other anti-parasitic compound is selected from the group consisting of milbemycins.
5. A composition according to claim 2, wherein the other anti-parasitic compound is selected from the group consisting of avermectins.
6. A composition according to claim 5, wherein the antiparasitic compound is
15 ivermectin.
7. A composition according to claim 6, wherein ivermectin is present in an amount in the range 0.1 to 10% (w/v).
8. A composition according to claim 2 or claim 3, wherein closantel is present in an amount of 1 to 30% (w/v).
- 20 9. A composition according to claim 1, wherein the delivery system comprises alcohols selected from the group consisting of primary, secondary, and tertiary aliphatic alcohols.
10. A composition according to claim 1, wherein the delivery system comprises alcohols selected from the group consisting of aromatic alcohols.
- 25 11. A composition according to claim 1, wherein the delivery system comprises alcohols selected from the group consisting of lower alkanols (C₁-C₆).

12. A composition according to claim 1, wherein the delivery system comprises polyethylene glycol, isopropyl alcohol and at least 20% ethanol.
13. A composition according to claim 1, wherein the delivery system comprises one or more polymeric moieties selected from the group consisting of polyethylene glycol, polyvinyl pyrrolidone and poloxamers.
14. A composition according to claim 13, wherein the polymeric moiety is present in an amount in the range of from 0.1%(w/v) to 80%(w/v).
15. A composition according to claim 13, wherein the polymeric moiety is present in an amount in the range of from 3%(w/v) to 20%(w/v).
16. A composition according to claim 13, wherein the polymeric moiety is polyvinyl pyrrolidone.
17. A composition according to claim 1, wherein the delivery system also comprises at least one of the following auxiliaries: surfactants, embittering denaturants (anti-licking), preservatives, spreading aids, penetration or occlusion enhancers, and anti-oxidants.
18. A composition according to claim 1, for use in eradicating adult flukes and immature flukes.
19. A composition as described in the formulation examples hereinbefore.



INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB2004/003006

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P33/14 A61K31/609 A61K31/365

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, CHEM ABS Data, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/010142 A1 (MIHALIK RICHARD) 24 January 2002 (2002-01-24) examples	1-9, 17-19
X	WO 00/04906 A (CROMIE LILLIAN ; DUFFY SEAN (GB); NORBROOK LAB LTD (GB)) 3 February 2000 (2000-02-03) claims	1-19
X	WO 97/13508 A (VIRBAC SA ; BEUVRY VINCENT (FR)) 17 April 1997 (1997-04-17) claims; examples	1-9
X	WO 95/05812 A (HARVEY COLIN MANSON ; ASHMONT HOLDINGS LTD (NZ)) 2 March 1995 (1995-03-02) examples	1-19
	----- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- '&' document member of the same patent family

Date of the actual completion of the international search

15 November 2004

Date of mailing of the international search report

06/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Venturini, F

INTERNATIONAL SEARCH REPORT

Int. Patent Application No
PCT/GB2004/003006

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	GB 2 386 067 A (NORBROOK LAB LTD) 10 September 2003 (2003-09-10) examples	1-19
A	----- SCHNEIDER, T. AND WHEELER, S.: "The efficacy of strategic treatments with ivermectin pour-on against trichostrongylid and lungworm infections in first year grazing calves in Northern Germany" ANGEW. PARASITOL., vol. 32, 1991, pages 185-192, XP009039805 JENA the whole document -----	1-19

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB2004/003006

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2002010142 A1	24-01-2002	US 6340672 B1 AU 3694901 A EP 1299108 A1 WO 0160380 A1	22-01-2002 27-08-2001 09-04-2003 23-08-2001
WO 0004906 A	03-02-2000	AU 5054099 A WO 0004906 A1 GB 2339691 A	14-02-2000 03-02-2000 09-02-2000
WO 9713508 A	17-04-1997	FR 2739778 A1 AU 7304196 A EP 0859609 A1 WO 9713508 A1	18-04-1997 30-04-1997 26-08-1998 17-04-1997
WO 9505812 A	02-03-1995	NZ 248486 A AU 695582 B2 AU 7469494 A EP 0724437 A1 WO 9505812 A1 ZA 9406195 A	26-07-1996 13-08-1998 21-03-1995 07-08-1996 02-03-1995 22-05-1995
GB 2386067 A	10-09-2003	WO 03072112 A1	04-09-2003

REVISED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 January 2005 (27.01.2005)

PCT

(10) International Publication Number
WO 2005/007241 A1

(51) International Patent Classification⁷: **A61P 33/14**,
A61K 31/609, 31/365

(21) International Application Number:
PCT/GB2004/003006

(22) International Filing Date: 12 July 2004 (12.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0316377.1 12 July 2003 (12.07.2003) GB

(71) Applicant (for all designated States except US): **NOR-
BROOK LABORATORIES LIMITED** [GB/GB]; Sta-
tion Works, Newry BT35 6JP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BLAKELY, William**
[GB/GB]; 79 Chapel Road, Killeavy, Newry, County Down
BT35 8JZ (GB). **CROMIE, Lillian** [GB/GB]; 65 Old War-
renpoint Road, Newry, County Down BT34 2PN (GB).

(74) Agent: **FITZPATRICKS**; 1 Blythswood Square, Glasgow
G2 4AD (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the revised international search
report: 10 March 2005

(15) Information about Correction:

see PCT Gazette No. 10/2005 of 10 March 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PARASITICIDAL COMPOSITION

(57) Abstract: An anti-parasiticide composition presented as a topical "pour-on" product for treating animals infected by parasites which are known to be susceptible to salicylanilides, especially closantel, alone or together with at least one other anti parasitic compound of the avermectin or milbemycin type and offers enhanced bioavailability of the salicylanilide by provision of a delivery system comprising at least 20%(v/v) of one or more alcohols, and optionally including a polymeric moiety selected from the group consisting of polyvinylpyrrolidone (PVP), polyoxypropylene/polyoxyethylene block copolymers (poloxamer), and polyethylene glycols (PEG), thereby improving the bioavailability of e.g. closantel (as assessed with respect to blood plasma levels of closantel).

WO 2005/007241 A1

INTERNATIONAL SEARCH REPORT

Inte Application No
PCT/GB2004/003006

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P33/14 A61K31/609 A61K31/365

CORRECTED VERSION

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, CHEM ABS Data, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/010142 A1 (MIHALIK RICHARD) 24 January 2002 (2002-01-24) examples	1-9, 17-19
X	----- WO 00/04906 A (CROMIE LILLIAN ; DUFFY SEAN (GB); NORBROOK LAB LTD (GB)) 3 February 2000 (2000-02-03) claims	1-19
X	----- WO 97/13508 A (VIRBAC SA ; BEUVRY VINCENT (FR)) 17 April 1997 (1997-04-17) claims; examples	1-9
X	----- WO 95/05812 A (HARVEY COLIN MANSON ; ASHMONT HOLDINGS LTD (NZ)) 2 March 1995 (1995-03-02) examples	1-19
	----- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

9 December 2004

Date of mailing of the international search report

22.12.2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Venturini, F

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/003006

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	GB 2 386 067 A (NORBROOK LAB LTD) 10 September 2003 (2003-09-10) examples	1-19
A	<p>-----</p> <p>SCHNEIDER, T. AND WHEELER, S.: "The efficacy of strategic treatments with ivermectin pour-on against trichostrongylid and lungworm infections in first year grazing calves in Northern Germany"</p> <p>ANGEW. PARASITOL., vol. 32, 1991, pages 185-192, XP009039805</p> <p>JENA the whole document</p> <p>-----</p>	1-19

INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No
PCT/GB2004/003006

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2002010142	A1	24-01-2002	US 6340672 B1	22-01-2002
			AU 3694901 A	27-08-2001
			EP 1299108 A1	09-04-2003
			WO 0160380 A1	23-08-2001
WO 0004906	A	03-02-2000	AU 5054099 A	14-02-2000
			WO 0004906 A1	03-02-2000
			GB 2339691 A	09-02-2000
WO 9713508	A	17-04-1997	FR 2739778 A1	18-04-1997
			AU 7304196 A	30-04-1997
			EP 0859609 A1	26-08-1998
			WO 9713508 A1	17-04-1997
WO 9505812	A	02-03-1995	NZ 248486 A	26-07-1996
			AU 695582 B2	13-08-1998
			AU 7469494 A	21-03-1995
			EP 0724437 A1	07-08-1996
			WO 9505812 A1	02-03-1995
			ZA 9406195 A	22-05-1995
GB 2386067	A	10-09-2003	WO 03072112 A1	04-09-2003